Company profile: Neuros Medical
1.1 - Company Overview
Company description
- Provider of neurostimulation therapies for patients with unmet medical needs, including the Altius System, a device designed to alleviate chronic post-amputation pain using bioelectric nerve block technology targeting sensory nerves; a patented on-demand high-frequency bioelectric nerve block to block pain signals in sensory nerves; and the QUEST Study, a clinical trial evaluating the safety and effectiveness of the Altius System for treating intractable post-amputation pain.
Products and services
- Altius System: Bioelectric device engineered to alleviate chronic post-amputation pain by applying a nerve block technology that precisely targets sensory nerves to reduce pain
- On-Demand Bioelectric Nerve Block: Patented technology that delivers high-frequency bioelectric signals to block pain signals in sensory nerves via a bioelectric nerve block mechanism
- QUEST Study: Clinical trial evaluating the safety and effectiveness of the Altius System for treating intractable post-amputation pain in patients with unmet medical needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neuros Medical
Prestwick Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic pharmaceutical drugs for chronic central nervous system diseases, offering products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea. Founded in 2002 and based in Washington, District of Columbia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prestwick Pharmaceuticals company profile →
Synchroneuron
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies under development for tardive dyskinesia and other related movement disorders, including lead candidate SNC-102, a sustained-release formulation of acamprosate calcium in phase 2 trials for tardive dyskinesia and Tourette syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synchroneuron company profile →
BioArctic
HQ: Sweden
Website
- Description: Provider of research-oriented biopharma solutions focused on neurodegenerative diseases, including Lecanemab—an antibody targeting amyloid-beta oligomers and protofibrils for Alzheimer’s—R&D of treatments addressing the cause of nerve cell damage in Parkinson’s disease and ALS, and brain transporter technology to enable drug delivery across the blood-brain barrier.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioArctic company profile →
Keros Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical discovery, development, and commercialization of novel treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Keros Therapeutics company profile →
Remedy Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule drug therapies for acute central nervous system disorders, developing treatments that target NCCa-ATP channels in traumatic brain injury, stroke, and spinal cord injury, including RP-1127, an intravenous glyburide inhibitor acting through type-1 sulfonylurea antagonism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remedy Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neuros Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neuros Medical
2.2 - Growth funds investing in similar companies to Neuros Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neuros Medical
4.2 - Public trading comparable groups for Neuros Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →